Aptar Pharma collaborates with Fluidda
The companies will leverage their respective proprietary technology platforms
The companies will leverage their respective proprietary technology platforms
Rabies claims around 59,000 deaths globally a year, of which around 20,000 or just over one-third of the deaths take place in India alone
The plant at Raleigh, North Carolina, USA owned by Aurolife Pharma has received an establishment inspection report (EIR)
Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
The ANDA was filed as 'First to File' submission on NCE-1 date.
Phase 2 study evaluating an investigational weekly oral combination treatment regimen of islatravir and Gilead Sciences’ lenacapavir to resume with lower dose of islatravir
Despite the technological advancements, there remains no alternative to blood and one unit of blood can save as many as three lives
These moves are designed to strengthen the company’s medical and scientific focus and support its continued record growth through closer alignment of all aspects of strategy, sales, and delivery to delight customers
Subscribe To Our Newsletter & Stay Updated